KORU Medical Systems, Inc. (KRMD) Stock Analysis and Metrics

KORU Medical Systems

NASDAQ: KRMD

$3.83 ▲ +0.10 (+2.68%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap177.58 Mn

P/E-63.28

P/S4.11

Div. Yield0.00

ROIC (Qtr)-0.03

Revenue Growth (1y) (Qtr)22.10

Add ratio to table…

About

KORU Medical develops, manufactures and commercializes innovative patient centric large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. The company’s core products are the FREEDOM Infusion System, which includes the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. These mechanical devices operate without batteries or electricity and are used primarily for delivering immunoglobulin to treat Primary Immunodeficiency Diseases and Chronic Inflammatory Demyelinating Polyneuropathy.

KORU Medical generates revenue from product sales of its infusion system components and from service agreements. Product revenue comes from sales of syringe drivers, tubing and needle sets to customers in the United States and Canada (domestic core) and to international markets (international core). Additionally, the company earns pharma services and clinical trials revenue by providing feasibility or early stage trial support and non recurring engineering services such as product adaptation, testing and regulatory assistance to biopharmaceutical firms developing new subcutaneous therapies.

The company operates through the following segments:.

• Pharma services and clinical trials: This segment provides product revenue for feasibility studies, clinical trials and non recurring engineering services including product innovation, testing and registration to help biopharmaceutical companies prepare and customize the FREEDOM System for commercial use across multiple drug categories.

Within the subcutaneous infusion market, KORU Medical holds a leading position, particularly as the market leading delivery system in the United States for immunoglobulin therapies. Its mechanical pumps compete with electronic volumetric pumps, elastomeric pumps and other mechanical devices, offering advantages such as no requirement for batteries or electricity, lower operating pressure, ease of use and lower total cost of ownership. These attributes support patient self administration and appeal to home infusion and specialty pharmacy settings.

The company serves specialty pharmacies, home infusion providers, medical device distributors and biopharmaceutical companies. Its products are used by patients receiving immunoglobulin therapy and by clinical sites conducting trials of new subcutaneous drugs.

Investment Thesis

▲ Bull case

KRMD's international expansion strategy is gaining significant traction beyond initial distributor orders, with strong end-user pull-through in prefilled syringe conversion markets across Europe, signaling durable growth rather than a one-time stocking benefit. The company's EU MDR clearance for Freedom60 with prefilled syringe compatibility enables deepening penetration in key markets like Germany, France, Italy, Spain, and the Benelux region, where pharma-driven vial-to-prefill conversions are accelerating. Unlike last year's pharma-tender-driven launches, this year's approach involves active collaboration with homecare providers and reimbursement bodies, which, while initially slower, builds more sustainable adoption as evidenced by Q1's 35% international core growth and the expectation of back-half revenue ramp-up. This structural shift positions KRMD to capture long-term share in Europe's growing subcutaneous infusion market, where local manufacturing advantages and regulatory alignment reduce dependency on volatile pharma tender cycles. The recent ONS Congress presentation further validates KRMD's clinical differentiation in oncology settings, showing reduced ergonomic strain for nurses and improved patient outcomes with FreedomEDGE®—a direct catalyst for broader ambulatory infusion clinic adoption beyond home use. This real-world evidence strengthens KRMD's value proposition against competitors in high-volume oncology channels, supporting Adam Kalbermatten's optimism about securing additional high-volume oncology assets beyond Phesgo, with potential to unlock multi-million dollar revenue streams as early as late 2026. The transition to Adam Kalbermatten as CEO on July 1st represents not just continuity but acceleration, as his deep commercial expertise in international markets and pipeline development—evident in his Q1 commentary—aligns with the company's three-pillar strategy execution. His focus on converting distributor orders into end-user pull-through, advancing next-generation platform development (Freedom360 pump submission targeted for late 2026), and expanding oncology indications internationally addresses the very concerns raised by analysts about growth deceleration, turning perceived risks into near-term catalysts. With $8.8 million in cash and access to an unused $10 million debt facility, KRMD has ample financial flexibility to fund these initiatives without dilutive financing, while maintaining progress toward its long-term $100 million revenue target and 65%+ gross margin goal through operating leverage from its recurring patient base of approximately 60,000.

KRMD's international expansion strategy is gaining significant traction beyond initial distributor orders, with strong end-user pull-through in prefilled syringe conversion markets across Europe, signaling durable growth rather than a one-time stocking benefit. The company's EU MDR clearance for Freedom60 with prefilled syringe compatibility enables deepening penetration in key markets like Germany, France, Italy, Spain, and the Benelux region, where pharma-driven vial-to-prefill conversions are accelerating. Unlike last year's pharma-tender-driven launches, this year's approach involves active collaboration with homecare providers and reimbursement bodies, which, while initially slower, builds more sustainable adoption as evidenced by Q1's 35% international core growth and the expectation of back-half revenue ramp-up. This structural shift positions KRMD to capture long-term share in Europe's growing subcutaneous infusion market, where local manufacturing advantages and regulatory alignment reduce dependency on volatile pharma tender cycles. The recent ONS Congress presentation further validates KRMD's clinical differentiation in oncology settings, showing reduced ergonomic strain for nurses and improved patient outcomes with FreedomEDGE®—a direct catalyst for broader ambulatory infusion clinic adoption beyond home use. This real-world evidence strengthens KRMD's value proposition against competitors in high-volume oncology channels, supporting Adam Kalbermatten's optimism about securing additional high-volume oncology assets beyond Phesgo, with potential to unlock multi-million dollar revenue streams as early as late 2026. The transition to Adam Kalbermatten as CEO on July 1st represents not just continuity but acceleration, as his deep commercial expertise in international markets and pipeline development—evident in his Q1 commentary—aligns with the company's three-pillar strategy execution. His focus on converting distributor orders into end-user pull-through, advancing next-generation platform development (Freedom360 pump submission targeted for late 2026), and expanding oncology indications internationally addresses the very concerns raised by analysts about growth deceleration, turning perceived risks into near-term catalysts. With $8.8 million in cash and access to an unused $10 million debt facility, KRMD has ample financial flexibility to fund these initiatives without dilutive financing, while maintaining progress toward its long-term $100 million revenue target and 65%+ gross margin goal through operating leverage from its recurring patient base of approximately 60,000.

▼ Bear case

KRMD's international growth remains overly dependent on distributor-led stocking patterns rather than proven end-user demand, creating significant near-term revenue volatility that management understated during the Q&A. Despite Adam Kalbermatten's optimism about EU prefilled syringe conversions, the company admitted that Q1's 35% international core growth was driven by "strong first quarter distributor orders" and a "bolus of pump orders" in new 50ml prefill markets, with Tom Adams explicitly noting they must "see that patient conversion happens" before expecting end-user pull-through—a dynamic that played out similarly in 2025 where initial distributor strength was followed by a lag before back-half ramp-up. This recurrence risk is amplified by the shift from pharma-tender-driven launches (which provided financial backing) to KRMD-led market conversion efforts requiring active collaboration with homecare partners and reimbursement bodies, a process Tom described as "a little bit slower" and inherently more variable across countries. Furthermore, the company's cautious stance on its Middle East distributor—citing geopolitical risk and absent order strength despite prior year exposure—reveals a pattern of overreliance on single distributors in emerging regions, where any disruption could erase what little international contribution exists outside core EU markets. Domestically, while KRMD outpaced the 8% SCIg market growth with 12% domestic core growth, this outperformance is increasingly tied to competitive account conversions and new patient starts in legacy accounts rather than organic market expansion, suggesting diminishing returns as the addressable patient base for primary immunodeficiency (PIg) nears saturation. The non-Ig pipeline, though highlighted as containing eight active opportunities representing 6 million annual infusions, remains largely preclinical or early-stage, with only two assets in Phase III trials (Apellis' Empaveli for DGF and an undisclosed partner's asset) and the deferoxamine 510(k) still pending—meaning near-term revenue contribution from these initiatives is expected to be merely "between $0.5 million and $1 million in 2026," a negligible fraction of the $47.5-$50 million guidance range. Management's refusal to quantify the Middle East geopolitical risk cushion—despite repeated analyst requests—signals unwillingness to disclose potential downside, especially given that oil price-driven freight increases (which Jason Bednar noted could impact Asia-sourced plastics) are not being monitored for material impact despite acknowledged supply chain vulnerabilities. Finally, the oncology opportunity, while framed as a $40 million market growing to $120 million, remains speculative: Phesgo's 510(k) is still under FDA review with no timeline for approval, and discussions about a second high-volume oncology asset are described as "early" with no concrete milestones, meaning any meaningful contribution is unlikely before 2027, leaving KRMD vulnerable to deceleration if its core SCIg business fails to sustain double-digit growth amid intensifying competition from larger infusion pump manufacturers leveraging scale in home and alternate site settings.

KRMD's international growth remains overly dependent on distributor-led stocking patterns rather than proven end-user demand, creating significant near-term revenue volatility that management understated during the Q&A. Despite Adam Kalbermatten's optimism about EU prefilled syringe conversions, the company admitted that Q1's 35% international core growth was driven by "strong first quarter distributor orders" and a "bolus of pump orders" in new 50ml prefill markets, with Tom Adams explicitly noting they must "see that patient conversion happens" before expecting end-user pull-through—a dynamic that played out similarly in 2025 where initial distributor strength was followed by a lag before back-half ramp-up. This recurrence risk is amplified by the shift from pharma-tender-driven launches (which provided financial backing) to KRMD-led market conversion efforts requiring active collaboration with homecare partners and reimbursement bodies, a process Tom described as "a little bit slower" and inherently more variable across countries. Furthermore, the company's cautious stance on its Middle East distributor—citing geopolitical risk and absent order strength despite prior year exposure—reveals a pattern of overreliance on single distributors in emerging regions, where any disruption could erase what little international contribution exists outside core EU markets. Domestically, while KRMD outpaced the 8% SCIg market growth with 12% domestic core growth, this outperformance is increasingly tied to competitive account conversions and new patient starts in legacy accounts rather than organic market expansion, suggesting diminishing returns as the addressable patient base for primary immunodeficiency (PIg) nears saturation. The non-Ig pipeline, though highlighted as containing eight active opportunities representing 6 million annual infusions, remains largely preclinical or early-stage, with only two assets in Phase III trials (Apellis' Empaveli for DGF and an undisclosed partner's asset) and the deferoxamine 510(k) still pending—meaning near-term revenue contribution from these initiatives is expected to be merely "between $0.5 million and $1 million in 2026," a negligible fraction of the $47.5-$50 million guidance range. Management's refusal to quantify the Middle East geopolitical risk cushion—despite repeated analyst requests—signals unwillingness to disclose potential downside, especially given that oil price-driven freight increases (which Jason Bednar noted could impact Asia-sourced plastics) are not being monitored for material impact despite acknowledged supply chain vulnerabilities. Finally, the oncology opportunity, while framed as a $40 million market growing to $120 million, remains speculative: Phesgo's 510(k) is still under FDA review with no timeline for approval, and discussions about a second high-volume oncology asset are described as "early" with no concrete milestones, meaning any meaningful contribution is unlikely before 2027, leaving KRMD vulnerable to deceleration if its core SCIg business fails to sustain double-digit growth amid intensifying competition from larger infusion pump manufacturers leveraging scale in home and alternate site settings.

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password